The HIV market continues to grow slowly but steadily in the US and EU thanks to increased testing, which has been facilitated by recent legislation (#msg-31419107), and new treatment guidelines that recommend an earlier start (#msg-33124429).
GILD’s Atripla/Truvada franchise continues to take market share from GSK’s ‡Epzicom/Kivexa, which is a now a very distant second among nucleoside backbones.
Here are data** on penetration and market share as provided by GILD on its 1Q09 CC:
US patients: All lines 175K on Atripla (31% share) 195K on Truvada (34% share) †20K on Viread (4% share) ==== 390K on tenofovir in some form (69% share) 175K on non-tenofovir regimens (31% share) ==== 565K total patients, +7% year-over-year, +1% quarter-over-quarter
US patients: First-line only Atripla or Truvada: >80% share (Atripla per se 50% share) ‡Epzicom: 6% share (down from 12% in 1Q08)
*EU patients: All lines 273K total patients, +7% year-over-year, +1% quarter-over-quarter
*EU patients: First-line only Atripla or Truvada: 73% share in 1Q09 (up from 70% in 4Q08) ‡Kivexa: 13% share in 1Q09 (down from 20% in 1Q08)
*Top-5 EU countries: Germany, France, UK, Italy, Spain. **As of the end of 4Q08 unless otherwise specified. †Estimate by Dew. ‡Epzicom (US) and Kivexa (EU) are the same product: a combination of GSK’s Epivir and Ziagen.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.